NCT04498169

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Dosing Regimens of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.

Conditions

• Corneal Edema

Interventions

Type	Name	Description
DRUG	Netarsudil Ophthalmic	Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
DRUG	Netarsudil Ophthalmic	Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

Timeline

• Start date: 2020-09-17
• Primary completion: 2021-08-11
• Completion: 2021-08-11
• First posted: 2020-08-04
• Last updated: 2022-09-15
• Results posted: 2022-09-01

Locations

12 sites across 1 country: United States

Regulatory

• FDA-regulated drug study